Cargando…

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms

Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bin, Li, Rui, Wu, Shuai, Liu, Xin, Ren, Jianlin, Li, Jing, Bi, Kaixin, Wang, Yanhong, Jia, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187902/ https://www.ncbi.nlm.nih.gov/pubmed/34123801 http://dx.doi.org/10.3389/fonc.2021.651541

Ejemplares similares

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of Tetrastigma hemsleyanum
por: Wei, Chaoguang, et al.
Publicado: (2022)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023)

Intricacies of Radiographic Assessment in Testicular Germ Cell Tumors
por: Makovník, Marek, et al.
Publicado: (2021)

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
por: Lin, Z. Ping, et al.
Publicado: (2018)

Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer
por: Guan, Liping, et al.
Publicado: (2022)

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models
por: Yin, Lei, et al.
Publicado: (2022)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
por: Merlini, Alessandra, et al.
Publicado: (2023)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022)

Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far
por: Prasad, Shashanka K., et al.
Publicado: (2022)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
por: Gao, Shan, et al.
Publicado: (2023)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Li, Bin-Bin, et al.
Publicado: (2019)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Intricacies of Pluripotency
por: Bhartiya, Deepa
Publicado: (2015)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Cyclin-Dependent Kinase 5 Regulatory Subunit Associated Protein 3: Potential Functions and Implications for Development and Disease
por: Sheng, Linna, et al.
Publicado: (2021)

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Revealing the intricacies of cancer
por: Verhagen, Anne M, et al.
Publicado: (2002)

Intricacy, Symmetry, Diversity
por: Breedlove, Byron
Publicado: (2020)

Intricacies of ribosomal frameshifting
por: Atkins, John F., et al.
Publicado: (1999)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
por: Pandey, Pratibha, et al.
Publicado: (2023)

Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner
por: Li, Kai, et al.
Publicado: (2022)

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma
por: Liu, Songlin, et al.
Publicado: (2019)

Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights
por: Du, Jiajia, et al.
Publicado: (2021)

Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex
por: Zhang, Jingxiao, et al.
Publicado: (2018)

β-catenin inhibitors in cancer therapeutics: intricacies and way forward
por: Dev, Arundhathi, et al.
Publicado: (2023)

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
por: Xie, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_735c04oh7kflo35dvnvrq3dcd3